Day1: May 27, 2019
Middlesex University London
10:00 - 10: 45
Dr. Konstantinos Papadopoulos has been Graduated from Alexandreio Technological Institute of Thessaloniki Greece, as Physiotherapist. He holds an MSc degree in Exercise Rehabilitation, a PhD degree in Healthcare Sciences (Bangor University, UK) whilst he is also a Higher Education Acedemy (HEA) fellow.
He is currently a Senior Lecturer in Sport Physiotherapy in the Faculty of Science and Technology, London Sports Institute and is the programme leader for the MSc Sport Rehabilitation programme. He is a HCPC registered physiotherapist with a focus on Musculoskeletal conditions of the lower limb.
Patellofemoral Pain (PFP) is a very common knee condition with various aetiologies. Most of the studies are individual approaches which aimed to explore the associated risk factors, assessment and treatment techniques or clinical tests that are related to PFP without the identification of the issues surrounding PFP and applied physiotherapy practice. The aim of this presentation was to facilitate a ‘collective’ case study approach that draws together a range of evidence from different ‘cases’. These cases are defined as areas of evidence underpinning PFP management as an applied physiotherapy phenomenon. This presentation reports the complexity of PFP in terms of the (i) evidence-base, (ii) the application of clear guidance, (iii) the actions of physiotherapists in the applied field context and (iv) and the fundamental dissonance rather than bridging of the evidence-base and applied practice.
Findings of our studies and the further synthesis indicated that a model of applied physiotherapy emerged from the collective case study, based on the discrete results from each respective case. A final model was generated as part of the synthesis that identified the dynamics of practice environments and accounted for the influence of different variables that impacted on the outcomes of physiotherapy practice delivering interventions in PFP. A model of applied physiotherapy is presented that articulates how PFP should be viewed as a complex intervention and that a modified Promoting Action on Research Implementation (PARIHS) framework should be utilised to address the deficits of clinical practice.
10:45 - 11:30
Yann de Cambourg is co-founder of Synodis, an innovative player in the healthcare sector based in Paris, France. Yann has developped expertise as a facilitator and accelerator in business transformation projects with a focus on Interoperability and Data sharing ; helping healthcare actors enter the patient data centric ecosystem.
What is the role of the patient, in the framework of his/her medical care? One of the illustrations of the development of the role of the patient is the structured coordination of the Common Cancer Record used in cancer care. In this context, when the disease is declared, a personalized care plan is established, and this plan can evolve ! This is an example of the fundamental change in the role of the patient, who becomes an actor of his own medical care with the support and advice of physicians.
Moreover in the coming years, improvements will come from genetic inheritance and lifestyle. Collecting patient data will be a necessay step ; patient consents will have to be managed. New skills will prevail around IOT or AI. The relations between actors is evolving : patient, citizen, physicians, EHR, ...
The physician is a connection between the Hospital and the outside world, with relations with town medical care (the patient physician), laboratories (medical, investigation, research), and peers (research, publications, etc).
Currently, the gap between the city and the hospital is being filled, partly through the development of outpatient care. This development is actually a major change of the role of health care institutions, which goes from being curative to being simple stage in the life journey. Physicians are positioned as coordinators of the course of care, but actually a whole chain of practitioners is involved in dealing with the patient.
Aribau 185, Barcelona, Spain
IT Engineer by the Universitat Autonoma Barcelona, expert in eHealth and chronic patient management models. Since 2015, General Manager for DomusVi Healthcare (DomusVi Spain), previously Business Development Manager at SARquavitae since 2011. He developped his career from the consulting area, where he workd as a Manager in the big brands such as PriceWaterhouseCoopers, ArthurAndersen and BearingPoint, where he developed several projects in the health sector. Some successful examples: Chronicity Strategy in Euskadi (Osakidetza) with Accenture, HCE deployment in Murcia Health Service with Siemens, IT Strategic Plan Hospital Sant Pau Barcelona with PwC.
Sara Nickerson White is a passionate researcher and evaluator. She firmly believes in the ability of collaborative research and evaluation to make a difference in the lives of children, youth and families. Due to her developed methodological expertise, and her continuous curiosity, Sara has been a successful researcher and program evaluator for over 15 years. She has designed implemented and managed research and evaluation projects for communities and agencies across all Canadian provinces and has managed large-scale national and international research projects. Currently, she is a professor at Humber College in the School of Community and Social Services
Ultimately this workshop asks: how do we, as health care practitioners, actively and deliberately do authentic collaboration when working with children, youth and families? It focuses on how practicing professionals can purposively develop the deep meaning of what is said (content) as it is said (context) and thus, improve the quality of care they provide. The goal of this workshop is twofold. First, to demonstrate the typical absence, yet necessity, of authentic collaboration when working with children, youth and families. Second, to detail four phenomenological hermeneutic (PH) tactics that provide a basis for doing the primary language work required to know, do and be authentic collaboration in one’s professional practice.
Inspired by the work of Parse (1998, 2001, 2005), informed by theorists such as Heidegger (1962) and Gadamer (1975), and rooted in the interpretive work of van Manen (1990); this workshop takes on a restructuring approach to consumer-practitioner communications. Moving away from techniques that typically re-center communications within the horizon of the professional ‘listener’, this work deeply considers the interpretive moment of being, knowing and doing authentic collaboration when in relation with children, youth and families.
Four PH authentic collaboration ‘tactics’ (de Certeau, 1984) are detailed. Tactics include: sense-making; truth, method and world recommended; ego, alter; and lived experience description. Each tactic is shown to guide the practitioner in the development of an ‘experience’ (Gadamer, 1975) that relies on an expansion of their possibilities of understanding given the finitude of their own professional horizon. Workshop participants will apply of these tactics using case study examples. By activating workshop content in this way workshop participants will live through the promise the PH professional practice approach holds for: strengthening the dynamic, self-aware, responsive and ethical nature of care (White, 2007) that children/youth/families deserve and that professional practice standards demand.
Day2: May 28, 2019
University of Campinas, Barcelona
10:00 - 10: 45
RN Luciana Teixeira Lot has been Graduated from University of Campinas, in Brazil, on 2003. With the specialties including Public Policies Management, Improvements in Health Care and Diploma in MBA Health Care Management. Later on she obtained her post-graduation from University of Campinas with subjects Implementation of Lean healthcare methodology in public health services and then started working at Liver Transplant Outpatient clinics, where she has continued her research. Presently she has been working at the at the Campinas University Hospital.
Luciana Lot, From Brazil Registered Nurse since 2003 Specialist in Intensive Care Unit MBA in Health Services Management Specialization in Public Management and Government by the Economic Institute of the University of Campinas, Master Degree candidate in Improvements in Health Care Services. Acting as a Registered Nurse in Pediatric and Oncology Intensive Care Unit, Bone Marrow Transplant, Neonatal Intensive Care Unit, and currently in a Outpatient Liver Transplant Unit, with emphasis on Nursing and Public Management. Speaker and Researcher of the Health Management and Innovation Group at University of Campinas, which was voted the best university in Latin America by the British publication Times Higher Education (THE). THE is known for the evaluation of international higher education institutions. Successful work carried out in the segment of continuous improvement in public health and reduction of patient waiting time.
All healthcare systems face the same challenge: improve quality of patient care, increase the number of patients served and reduce costs and waiting times. Lean Healthcare is a management methodology that takes no more than few hours of observation on the front lines to uncover opportunities for improvement. These study was focused on the patient waiting time and health care environmental and aims to address problems at patient flow and the reasons behind long wait times in a public Liver Transplant outpatient clinic at an education and research hospital, using Lean Healthcare theories.
The project is to improve the liver transplant patient's journey using Lean Healthcare tools. The project was guided by A3 thinking, a visual and simple methodology to follow up on an improvement project (one of the Lean tools). After the Value Stream Mapping, we identified 3 initial improvement opportunities that were implemented. However, we intend to continually improve the patient's experience through the Lean methodology. So far, we have been able to reduce the waiting time by 4:30 and improve the "complete correct" phase of the process by 50%. Such improvements have helped not only patients, who wait less, but also reduced rework waste and improved employee relationships. It is important to emphasize that the use of the Lean methodology aid in the team learning process for continuous improvement and culture change.
Dr. Roser Francisco is a registered nurse and a biologist, and has completed her PhD on Biomedicine from the University of Barcelona. She is the Head of the rare diseases program of the Catalan Health Servicie (CatSalut), a public health administration. Her work has always been related to rare disesases, from research to health planning. Thanks to her experience she has an holistic knowledge of RD’s needs: doctoral thesis on the rare paediatric oncologic disease neuroblastoma, advice and monitoring of clinical trials in rare diseases, participation in the wording and implementation of the Catalan RD’s Care Model.
People living with rare diseases (RD) are vulnerable to healthcare systems because standard procedures are not adequate for these patients. Catalonia’s Health Ministry has been working since 2009 on different health policies that seek to improve awareness, diagnosis and treatment of people affected by RD.
One of these policies defines the Catalan RD Care Model. This model aims to achieve a person-centred care and to guarantee equity of access to speciealized care; it integrates the different patient care levels and optimizes the resources available by identifying and guaranteeing the access to clinical reference units (UEC) which are responsable for leading an integrated care network in collaboration with the territorial/community level (the one close to the home of the patient: includes primary healthcare, territorial hospitals and other health services as well as social, educational and labour resources). The integrated care network implies a collaborative attitude and depends largely on eHealth tools usage.
The model has been designed with the advice of a RD Advisory Committee (CAMM) and takes into account the viewpoint of patients, clinicians and professionals of different administration bodies (health, welfare and education). Furthermore it is aligned with the RD national and European strategies (Estrategia nacional de Enfermedades raras and European Reference Networks -ERNs-).
The model implementation process has been designed by phases; RDs are grouped in thematic groups (similar to ERN grouping) which are priorized and worked in collaboration with professional experts of our territory. In 2017, the first catalan network was designated, it addresses genetic cognitive behavioural diseases. At least two more networks will be designated during 2018.
Yarmouk University, Irbid, Jordan
Dr. Ahmad Khalil received Ph.D. in Cytogenetics from Ohio State University in 1987. Since 2000 a Professor of Molecular Cytogenetics at Yarmouk University, JORDAN. Chaired Department of Biological Sciences at Yarmouk 2001-2003. Founded Biotechnology M. Sc. Program at Yarmouk in 2003. Published 48 research papers most of them in peer reviewed International Journals. Research interest in biotechnology cell culture techniques and their applications in environmental health. Developed and expanded expertise in investigating biology of prostate cancer. Active reviewer and member in Editorial Board of several local, regional and International Journals. Participated in more than 40 conferences, training courses and workshops world-wide
Ivermectin (IVM) is widely used in human and veterinary medicine for the control of parasitic infections. Researches revealed new avenues of medicinal applications of IVM as an antiviral and an anticancer agent. Very little is known about the genotoxic potential of IVM and the available literature is contradictory. The objective of this study was to evaluate the possible genetic damage caused by IVM. Male Sprague Dawley rats were intraperitoneally given IVM at doses between 0.2mg and 3.2mg/kg body weight (b. w). Percentage of mitotic and aberrant bone marrow cells were followed. The results indicated that IVM by itself, at doses higher than the recommended dose, induced significant levels of cytogenetic toxicity. To this end, we decided to investigate the potential use of combination of varying doses of aged garlic extract (AGE); 300, 600 and 1200 mg/kg b w and the minimum detectable toxic (MTD) dose of IVM; 0.4 mg/kg. A powerful capacity of AGE to reduce IVM cytogenetic effects was demonstrated. Overall, the data prove the safety of IVM at the recommended dose and provide a strong scientific evidence for superior protection of AGE against possible cytogenotoxic side effects of IVM, confirming the existence of a meaningful therapeutic window.